Twitxy Saved

Nick Leeper

@NickLeeper78

Joined December 2022
376 Following 331 Followers 304 Posts

Latest posts 5

Nick Leeper @NickLeeper78
And if the clinical training, first-in-human trials, and awesome collaborative spirit aren’t enough, pretty sure we are the only program with a “Vascular Dogtor” on the team!
Gaurav Parmar MD MPH Verified account @GParmar_MD Oct 20
🚨Shape the future of Vascular Medicine. Train at Stanford alongside @NickLeeper78, @EriFukayaMD, @AHAthavale, & fabulous VS team @StanfordVasc

Complex vascular care
Cutting-edge research
Exceptional mentorship
Endless opportunities to innovate

Apply👇
vascular.stanford.edu/education/vasc…
View quoted post on X
3 replies 2 reposts 25 likes 567 views View on X
Nick Leeper @NickLeeper78
Wow, awesome news Javid! As you know, Ricky is one of the brightest and most talented scientists that has ever come through my lab. And probably the nicest guy you could ever meet. Skys the limit for @ScientistBaylis! Cant wait to see what you two discover together.
Javid Moslehi @CardioOncology Sep 23
View quoted post on X
0 replies 0 reposts 10 likes 633 views View on X
Nick Leeper @NickLeeper78
Very fun collaborating on this piece with you Cam. Was great to learn about these important models as our lab ventures into environmental exposures, and especially the role of microplastics in atherosclerosis.
Check out our review on modeling the exposome in murine cardiovascular disease! We need to expand holistic whole organism models to study lifestyle and environmental impacts on health to identify evolutionarily selected inter-organ mechanisms that can be therapeutically harnessed
View quoted post on X
Nick Leeper @NickLeeper78
Totally agree. Amazing to see so many of the key atherogenic lipids wiped out simultaneously. And fun to think of all the opportunities a dual targeting platform provides. siRNA-based “polypills”!
John Maraganore 🇺🇸🇬🇷🇺🇦 Verified account @JMaraganore Sep 15
I’m very excited about these dimer data from @ArrowheadPharma!

There’s a very exciting future for bispecific RNAi, further expanding the patient impact of this modality!
View quoted post on X